Drug: Ibogaïne

What It Is

Ibogaine is a single compound, a monoterpene indole alkaloid, extracted from the root bark of Tabernanthe iboga, a shrub used ceremonially in West Central Africa. Researchers have studied it for one purpose above all: interrupting addiction, and opioid dependence most of all.

A single large dose is reported to ease withdrawal for days; standard opioid-agonist treatment, methadone or buprenorphine, is taken daily and indefinitely. Ibogaine draws attention for two reasons. One is an early, repeated signal that it helps some people whom other treatments have failed. The other is a documented danger of sudden death from a disturbed heart rhythm.

What It Does

In an observational study of 30 people dependent on opioids, a single dose dropped withdrawal scores from 31.0 to 14.0 on a 0-to-64 scale within about three days. At one month, half reported no opioid use in the previous 30 days. Drug-use severity was still improved out to 12 months, though below the one-month peak.

A separate 12-month study followed 14 people treated legally in New Zealand. A year later they used fewer opioids and scored lower for depression. One of the 14 died during treatment.

The strongest recent work is a 2024 Stanford study of 30 male Special Operations veterans, most with mild brain injury. A single treatment of ibogaine with magnesium was followed a month later by large gains in functioning, post-traumatic stress, depression, and anxiety.

All of this evidence is the same weak quality: small, open-label, no control group. No one was blinded, everyone chose and often paid to be there, and each study was small. That combination inflates the apparent benefit. It cannot separate the drug from expectation, from the detox care given alongside, or from the natural course of withdrawal. No adequate randomized controlled trial has been completed, and the field's own reviews call the results preliminary.

The Research & Studies

Everything here is based on the research we have collected and checked, sorted into groups and ordered with the strongest evidence first. Click any claim to open the studies behind it.

How it works

Les alcaloïdes iboga bloquent le canal potassique hERG, le mécanisme à l'origine de l'allongement du QTModerate · risk

In plain terms

L'ibogaïne et ses proches bloquent un canal cardiaque spécifique appelé hERG, ce qui est la raison biologique pour laquelle le médicament perturbe le rythme cardiaque.

In detail

Dans des études cellulaires, l'ibogaïne et les alcaloïdes iboga apparentés bloquent le canal potassique hERG qui repolarise le cœur. La perte de ce courant allonge l'intervalle QT et crée le substrat électrique sur lequel un rythme dangereux peut naître. Measured in: hERG channels expressed in cell systems. Le travail cellulaire mécanistique explique comment le risque survient mais ne permet pas à lui seul de prédire la dose ou la personne chez qui un rythme dangereux surviendra.

The study · 1

Alper et al., hERG blockade by iboga alkaloids · Cardiovasc Toxicol 2016;16(1):14-22

Addiction

Opioid withdrawal scores fell by more than half within three days, and half the group reported no opioid use a month laterPreliminary

In plain terms

In 30 people with opioid dependence, withdrawal symptoms dropped by more than half within three days of a single ibogaine dose, and one month later half reported no opioid use, but there was no comparison group.

In detail

In an observational study of 30 adults with opioid dependence, Subjective Opioid Withdrawal Scale scores fell from 31.0 to 14.0 on a 0 to 64 scale within about 76 hours of a single ibogaine dose, and at one month 15 of 30 (50%) reported no opioid use in the previous 30 days, with drug-use severity still improved from 3 to 12 months though below the one-month peak. Measured in: 30 adults with DSM-IV opioid dependence (25 men, 5 women) treated at a clinic in Mexico. What could explain it instead: Self-selection into a private overseas clinic, no comparison group, and concurrent detoxification and aftercare all sit between the drug and the outcome.. Un seul groupe sans témoin et sans insu, chez 30 patients auto-sélectionnés, si bien que le changement ne peut être distingué des soins de désintoxication concomitants, de l'attente ou de l'évolution naturelle du sevrage.

The study · 1

Brown & Alper, treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes · Am J Drug Alcohol Abuse 2018;44(1):24-36

Un traitement unique suivi d'une réduction de l'usage d'opioïdes et de scores de dépression plus bas s'est maintenu sur 12 mois, et un participant est décédé pendant le traitementPreliminary

In plain terms

Parmi 14 personnes traitées légalement en Nouvelle-Zélande, l'usage d'opioïdes et les scores de dépression étaient plus bas un an après un traitement unique à l'ibogaïne, mais seules 8 ont terminé l'étude et une personne est décédée pendant le traitement.

In detail

Parmi 14 Néo-Zélandais ayant reçu de l'ibogaïne légale pour dépendance aux opioïdes, la sévérité de l'usage de drogue mesurée par l'Addiction Severity Index-Lite a diminué significativement entre le départ et 12 mois chez les 8 ayant terminé tous les entretiens (p = 0.002), la dépression mesurée par le BDI-II a également diminué (p < 0.001), et les scores de sevrage ont chuté de façon aiguë après le traitement chez les 14 (p = 0.015). Un des 14 est décédé pendant le traitement. Measured in: 14 adults with opioid dependence (50% female) treated legally in New Zealand. What could explain it instead: No comparison group, heavy dropout, self-selection, and treatment providers working alongside other health professionals mean the reduction cannot be attributed to ibogaine alone.. Seuls 8 des 14 ont terminé le suivi, il n'y avait pas de groupe témoin, et un participant est décédé pendant le traitement, si bien que le bénéfice et le risque proviennent de la même petite série.

The study · 1

Noller et al., ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study · Am J Drug Alcohol Abuse 2018;44(1):37-46

Mood & stress

Chez des vétérans avec lésion cérébrale, le fonctionnement, le SSPT, la dépression et l'anxiété se sont améliorés un mois après la magnésium-ibogaïnePreliminary

In plain terms

Trente vétérans masculins ayant des lésions cérébrales ont connu de fortes améliorations du fonctionnement, du SSPT, de la dépression et de l'anxiété un mois après un traitement unique à la magnésium-ibogaïne, mais il n'y avait pas de groupe témoin et tout le monde savait qu'il recevait le médicament.

In detail

Chez 30 vétérans masculins des forces spéciales avec un traumatisme crânien majoritairement léger, les scores de handicap se sont améliorés un mois après un traitement unique à la magnésium-ibogaïne (d de Cohen = 2.20), avec de fortes réductions du SSPT (d = 2.54), de la dépression (d = 2.80) et de l'anxiété (d = 2.13). Le magnésium était co-administré pour atténuer le risque cardiaque, et aucun événement indésirable grave n'a été rapporté. Measured in: 30 male Special Operations Forces veterans with predominantly mild TBI (Stanford MISTIC protocol). What could explain it instead: No comparison group, self-selected veterans who traveled abroad for treatment, complementary therapies given alongside the drug, and investigator financial interests all bear on the result.. Étude ouverte, sans groupe témoin, administrée avec d'autres thérapies, et menée par une équipe détentrice de brevets connexes, si bien que les très grandes tailles d'effet restent provisoires et non contrôlées en insu.

Who this may not transfer to:Measured only in male Special Operations veterans. It has not been tested in women, and injury type, cardiac risk and hormonal factors differ by sex, so whether the same effect holds in women is unknown.

The study · 1

Cherian et al., magnesium-ibogaine therapy in veterans with traumatic brain injuries · Nat Med 2024;30(2):373-381

Evidence And Methods

Aucun essai contrôlé randomisé adéquat n'a testé l'ibogaïne pour la dépendance ; les preuves d'efficacité sont issues d'études ouvertes et non contrôléesPreliminary · mixed

In plain terms

Il n'existe encore aucun essai randomisé rigoureux de l'ibogaïne pour la dépendance ; tous les résultats encourageants proviennent d'études où tout le monde savait qu'il recevait le médicament et sans groupe de comparaison.

In detail

En 2024, les preuves d'efficacité humaine de l'ibogaïne dans le trouble de l'usage de substances proviennent d'études ouvertes et observationnelles sans insu et sans groupe témoin. Aucun essai contrôlé randomisé adéquat n'a été mené à terme, et les revues du domaine elles-mêmes qualifient les résultats de préliminaires et nécessitant des essais contrôlés. Measured in: the published human literature on ibogaine for substance-use disorder. Sans groupe témoin randomisé, l'ampleur d'un effet réel est inconnue, et l'attente ainsi que l'évolution naturelle de la dépendance ne peuvent être distinguées de l'effet du médicament.

The study · 1

Cherian et al., psychedelic therapy: a primer for primary care clinicians, ibogaine · Am J Ther 2024;31(2):e133-e140

The same studies that report benefit also record deaths.

A review of all known fatalities outside West Central Africa from 1990 to 2008 found 19 people who died within 1.5 to 76 hours of taking ibogaine, most of them with preexisting heart disease or other drugs also present.

How It Works

Ibogaine does not act on one clean target. It binds serotonin and opioid receptors, NMDA glutamate receptors, sigma receptors, and nicotinic receptors. The liver converts it into a long-lived metabolite, noribogaine, that stays active for days and carries much of the drug's continuing effect. No single one of these actions has been shown to be why craving falls, so the mechanism behind the addiction signal is still open.

The cardiac action is better understood. Ibogaine and its metabolite block the hERG potassium channel, the current that resets each heart cell after a beat. Cut that current and the electrical recovery lengthens, seen on an electrocardiogram as a prolonged QT interval. A long QT is the setting where a chaotic, sometimes fatal rhythm called torsades de pointes can start. The effect grows with the dose and worsens when the heart is already stressed or potassium or magnesium is low. That dose-related danger is why the Stanford protocol pairs ibogaine with magnesium.

What Happens in the Body

1The acute experience

A large dose produces many hours of a dreamlike, waking state, often with vivid imagery, over roughly a day, followed by a long period of reduced sleep. This is the window in which withdrawal is reported to ease. It also overlaps the window in which the dangerous heart-rhythm changes occur, which is why the research settings that use it keep a person on continuous cardiac monitoring.

2The lingering metabolite

Because noribogaine persists for days, part of any lasting effect on craving is attributed to it. The hERG blockade, and the QT prolongation with it, also continues past the acute experience.

3The heart under load

A prolonged QT is where a fatal arrhythmia can start. The danger is greatest with existing heart disease, low potassium or magnesium, other QT-prolonging drugs on board, or a large or repeated dose.

The Legal Position

Ibogaine is Schedule I in the United States, the most restricted category. Outside authorized research its use is illegal, and it is not an approved treatment anywhere in the country.

Most human experience comes from clinics in Mexico, in parts of Central America and the Caribbean, and a few other countries. They operate with little or no medical regulation, varying widely in whether they screen the heart before treatment or monitor it during. New Zealand is unusual in permitting ibogaine under a controlled arrangement, which is why one of the better follow-up studies could be done there.

Go Deeper

• Psychedelics in mental health: the wider group of supervised, trial-stage compounds that ibogaine sits within, from psilocybin to MDMA.
• Meditation and mindfulness: a low-risk way to work with a craving or distressed mind that you can start on your own, and the grounding practice the Chinese medicine view points to first.
• Purpose and meaning: the sense of meaning that steadies a person through recovery, approached as a practice in its own right.

The Chinese Medicine View

Chinese medicine has a long-standing frame for intense altered states and for the pull of a substance, and it treats both with caution. The Heart is said to house the Shen, the spirit and consciousness. Clear thought, steady emotion, and settled sleep are read as signs of a rooted Shen. A mind overwhelmed by vivid imagery, disoriented or agitated, is read as a disturbance of the Shen. The classical instinct is to calm and anchor such a state.

A long, overwhelming drug experience could be seen as forcibly stirring the Shen. The tradition would approach that with great care, especially in someone depleted by years of addiction, and especially where the Heart itself carries the physical risk. Addiction, in this frame, is often read as an empty state a person tries to fill, and the classical response is to nourish and root it. The wider preventive tradition of Yang Sheng, nourishing life, would put grounding practices and steady support first.

Cautions For This Practice

Everything to be aware of is here, in one place. This practice suits most healthy people; a few situations call for real care.

L'ibogaïne a été suivie de troubles du rythme cardiaque mortels ; une revue a recensé 19 décès peu après sa prise

Une revue systématique de tous les décès connus survenus en dehors de l'Afrique centrale occidentale entre 1990 et 2008 a recensé 19 personnes (15 hommes, 4 femmes, âgées de 24 à 54 ans) décédées entre 1.5 et 76 heures après la prise d'ibogaïne. Des affections médicales préexistantes, principalement cardiovasculaires, et/ou une ou plusieurs substances abusées expliquaient ou contribuaient au décès dans 12 des 14 cas disposant de données d'autopsie adéquates. Une série de cas dénombre des décès sans dénominateur, donc elle ne peut fournir un taux, mais elle établit que des issues fatales surviennent, le plus souvent en présence d'une maladie cardiaque ou d'autres substances.Alper et al., fatalities temporally associated with the ingestion of ibogaine

L'ibogaïne allonge l'intervalle QT et peut déclencher des troubles du rythme cardiaque potentiellement mortels

Une revue des effets cardiaques de l'ibogaïne rapporte qu'elle allonge l'intervalle QT et a été associée à une accumulation de rapports d'arythmies potentiellement mortelles et de mort subite, un effet attribué au blocage du canal potassique cardiaque hERG, le métabolite à longue durée de vie, la noribogaïne, présentant la même action. Une revue narrative rassemble des rapports existants, sans tester le risque dans un groupe défini, elle décrit donc le danger sans quantifier sa fréquence.Koenig & Hilber, the anti-addiction drug ibogaine and the heart: a delicate relation

Ibogaine has caused fatal cardiac arrhythmias

Anyone with a heart condition, a long-QT tendency, low potassium or magnesium, or other QT-prolonging medication is at serious risk. This page carries no dosing, no sourcing, and no instructions for use.

The interactions that raise the danger

The cardiac risk climbs when ibogaine is combined with other drugs that prolong the QT interval, including some antidepressants, antipsychotics, and antibiotics, and when potassium or magnesium is low. Because ibogaine also acts on serotonin and opioid systems, combining it with opioids or serotonergic medication carries its own hazards. Anyone on medication is in territory where these interactions have caused deaths.

The evidence is a signal, not a settled treatment

The results that draw people to ibogaine come from small, uncontrolled studies, so the true size of the benefit is unknown. Treatments with a randomized-trial base exist, and clinical trials are recruiting.

Ibogaine shows an early signal for a problem that current treatments often fail, and it carries a documented risk of sudden cardiac death. Weigh the evidence at its real, preliminary strength. Treat the cardiac risk as the central fact. For your own care, talk to a qualified clinician.

Common Questions

Does ibogaine work for opioid addiction?

The early evidence points that way, with one heavy caveat: it has never been through a randomized trial. A single dose can interrupt use for months in some people, even where standard treatments have failed. But the studies are small and uncontrolled. That leaves ibogaine a preliminary signal, well short of a proven treatment.

Why is ibogaine dangerous?

Because it can stop the heart. Ibogaine lengthens the heart's electrical recovery, and in the wrong conditions that can tip into a fatal rhythm. The danger climbs in anyone with existing heart disease, in anyone whose potassium or magnesium runs low, in anyone on other QT-prolonging medication, and at higher doses.

Is ibogaine legal?

Not in the United States, where it is Schedule I and no clinic may offer it as treatment. That status does more than bar patients. It makes the controlled trials the field keeps asking for slow and costly to run, so the evidence stays thin in part because of the law itself. Most use happens in clinics abroad with little oversight.

What is the Stanford veterans study, and does it change the picture?

It is the most rigorous recent work, and it is still preliminary. In the 2024 Stanford study, 30 veterans given ibogaine with magnesium improved markedly a month later. What it cannot do is settle the question. With no control group and no blinding, expectation cannot be separated from the drug. For now ibogaine is still just a serious signal: the randomized trial that would confirm it has not been run.